NEW YORK (GenomeWeb News) – Precision BioSciences today responded to a lawsuit filed last week against it by Cellectis, which claims the Research Triangle Park, NC-based firm is infringing two Cellectis patents that cover meganuclease recombination systems, by saying that “no such infringement has occurred.”
Cellectis filed the suit last week in the US District Court for the Eastern District of North Carolina Western Division. The French firm alleged that Precision Bio infringed US Patent Nos. 7,309,605 and 6,610,545 — both of which are entitled “Nucleotide Sequence Encoding the Enzyme I-SceI and the Uses Thereof.”
The patents describe methods of using Group I intron encoded endonucleases to produce a site-directed double-stranded break in DNA for promotion of genetic recombination in organisms. Cellectis holds exclusive rights to the patents, which are owned by Institut Pasteur and Universite Pierre et Marie Curie.
According to Cellectis’ complaint, “Precision has been and is making Group I intron encoded endonucleases that are specifically intended for use by others in methods for inducing at least one site-directed double-stranded break in the DNA of an organism.”
“It is clear that our next-generation genome engineering technology is demonstrably distinct from the dated technology covered by Cellectis’ patents,” Precision Bio CEO Matthew Kane said in a statement. “This lawsuit appears to stem from a fundamental misunderstanding of Precision’s DNE technology and how it is employed.”